Targeted therapy is one of the mainstays for NSCLC, and it mainly includes antiangiogenesis drugs, drugs targeting epidermal growth factor receptor (EGFR) mutations, drugs targeting anaplastic lymphoma kinase gene alterations, and drugs targeting reactive oxygen species-1 gene alterations, which play a key role in improving the quality of life of patients and prolonging the progression-free survival (PFS) and overall survival (OS) [2, 3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.